1. Alternative treatments for breast cancer

   • E. Ernst

   Editorial 14 December 2011 Pages: 453 - 454

2. Clinical trials during pregnancy: what has been done

   • Viviana Domínguez
   • Nuria Ramos
   • Xavier Carné

   Review Article 11 November 2011 Pages: 455 - 458

   

3. Exposed or not exposed? Exploring exposure classification in studies using administrative data to investigate outcomes following medication use during pregnancy

   • Luke E. Grzeskowiak
   • Andrew L. Gilbert
   • Janna L. Morrison

   Review Article 13 November 2011 Pages: 459 - 467

   

4. Effect of erythropoiesis-stimulating agents in acute ST-segment elevation myocardial infarction: a systematic review

   • Juan Li
   • Huiyan Xu
   • Yanting Wen

   Review Article 16 November 2011 Pages: 469 - 477

   

5. Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases

   • P. Zarogoulidis
   • N. Papanas
   • K. Zarogoulidis

   Review Article 22 November 2011 Pages: 479 - 503

   

6. Off-label use of anti-cancer drugs between clinical practice and research: the Italian experience

   • Rosa Lerose
   • Pellegrino Musto
   • Alfredo Tartarone

   Review Article 14 December 2011 Pages: 505 - 512

7. Role of p38 inhibition in cardiac ischemia/reperfusion injury

   • Sarawut Kumphune
   • Siriporn Chattipakorn
   • Nipon Chattipakorn

   Review Article 29 December 2011 Pages: 513 - 524

8. Fluoroquinolone-induced liver injury: three new cases and a review of the literature

   • Anna Licata
   • Claudia Randazzo
   • Antonio Craxì

   Review Article 14 January 2012 Pages: 525 - 532

9. Hemodynamics and pharmacokinetics of tezosentan, a dual endothelin receptor antagonist, in patients with cirrhosis

   • Didier Lebrec
   • Jaime Bosch
   • Jasper Dingemanse

   Clinical Trial 20 November 2011 Pages: 533 - 541

   

10. The practical application of adaptive study design in early phase clinical trials: a retrospective analysis of time savings

    • U. Lorch
    • K. Berelowitz
    • J. Taubel

    Clinical Trial 25 November 2011 Pages: 543 - 551

    

11. Effect of Ginkgo biloba special extract EGb 761® on human cytochrome P450 activity: a cocktail interaction study in healthy volunteers

    • G. Zadoyan
    • D. Rokitta
    • U. Fuhr

    Clinical Trial Open access 21 December 2011 Pages: 553 - 560

12. Anti-epidermal growth factor receptor therapy for advanced head and neck squamous cell carcinoma: a meta-analysis

    • Shoude Zhang
    • Jia Chen
    • Beibei Yang

    Clinical Trial 10 January 2012 Pages: 561 - 569

    

13. Metabolism of alprazolam (a marker of CYP3A4) in hemodialysis patients with persistent inflammation

    • Hadi Molanaei
    • Peter Stenvinkel
    • Leif Bertilsson

    Special Article 09 December 2011 Pages: 571 - 577

    

14. Dose–response relationships of rabeprazole 5, 10, 20, and 40 mg once daily on suppression of gastric acid secretion through the night in healthy Japanese individuals with different CYP2C19 genotypes

    • Seiichi Hayato
    • Setsuo Hasegawa
    • Akihiro Ohnishi

    Pharmacodynamics 23 November 2011 Pages: 579 - 588

    

15. Repeat-dose sirolimus pharmacokinetics and pharmacodynamics in patients with hepatic allografts

    • Jürg Reichen
    • Felix Stickel
    • Joan Korth-Bradley

    Pharmacodynamics 06 December 2011 Pages: 589 - 597

    

16. Mixed-effect circadian rhythm model for human erythrocyte acetylcholinesterase activity—application to the proof of concept of cholinesterase inhibition by acorn extract in healthy subjects with galantamine as positive control

    • Seunghoon Han
    • Jongtae Lee
    • Dong-Seok Yim

    Pharmacodynamics 30 December 2011 Pages: 599 - 605

    

17. Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile

    • Andreas Clemens
    • Joanne van Ryn
    • Sebastian Härtter

    Pharmacodynamics Open access 18 January 2012 Pages: 607 - 616

    

18. Factor VII R353Q genetic polymorphism is associated with altered warfarin sensitivity among CYP2C9 *1/*1 carriers

    • Liat Mlynarsky
    • Idit Bejarano-Achache
    • Yoseph Caraco

    Pharmacogenetics 10 November 2011 Pages: 617 - 627

    

19. Evaluation of lansoprazole as a probe for assessing cytochrome P450 2C19 activity and genotype–phenotype correlation in childhood

    • Ersin Gumus
    • Ozgur Karaca
    • Umit Yasar

    Pharmacogenetics 11 November 2011 Pages: 629 - 636

    

20. CYP2D6 genotype and dextromethorphan hydroxylation phenotype in an Ecuadorian population

    • Pedro Dorado
    • Natalia Heras
    • Adrián LLerena

    Pharmacogenetics 15 November 2011 Pages: 637 - 644

    

21. Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics

    • Meghan Brennan
    • J. Andrew Williams
    • Yingxue Cathy Liu

    Pharmacogenetics 15 December 2011 Pages: 645 - 655

    

22. Clinical and genetic factors affecting tacrolimus trough levels and drug-related outcomes in Korean kidney transplant recipients

    • In-Wha Kim
    • Yoo Jin Moon
    • Jung Mi Oh

    Pharmacogenetics 20 December 2011 Pages: 657 - 669

    

23. The interactions of age, sex, body mass index, genetics, and steroid weight-based doses on tacrolimus dosing requirement after adult kidney transplantation

    • P. Stratta
    • M. Quaglia
    • C. Magnani

    Pharmacokinetics and Disposition 20 November 2011 Pages: 671 - 680

    

24. Fluconazole but not the CYP3A4 inhibitor, itraconazole, increases zafirlukast plasma concentrations

    • Tiina Karonen
    • Jouko Laitila
    • Janne T. Backman

    Pharmacokinetics and Disposition 23 November 2011 Pages: 681 - 688

    

25. The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis

    • Tanuja N. Gengiah
    • Nicholas H. G. Holford
    • Salim S. Abdool Karim

    Pharmacokinetics and Disposition 23 November 2011 Pages: 689 - 695

    

26. Intestinal OATP1A2 inhibition as a potential mechanism for the effect of grapefruit juice on aliskiren pharmacokinetics in healthy subjects

    • Sam Rebello
    • Sally Zhao
    • Venkateswar Jarugula

    Pharmacokinetics and Disposition 29 November 2011 Pages: 697 - 708

    

27. Pharmacokinetic drug interaction between gemfibrozil and sitagliptin in healthy Indian male volunteers

    • Arun K. P.
    • Venkata Subbaiah Meda
    • Suresh B.

    Pharmacokinetics and Disposition 16 December 2011 Pages: 709 - 714

    

28. Lack of a pharmacokinetic drug-drug interaction with venlafaxine extended-release/indinavir and desvenlafaxine extended-release/indinavir

    • Michael W. Jann
    • Vicky Spratlin
    • Chad VanDenBerg

    Pharmacokinetics and Disposition 16 December 2011 Pages: 715 - 721

    

29. Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase

    • Richard A. Larson
    • Ophelia Q. P. Yin
    • Philipp D. le Coutre

    Pharmacokinetics and Disposition 30 December 2011 Pages: 723 - 733

    

30. Population pharmacokinetics of prophylactic cefoxitin in patients undergoing colorectal surgery

    • Arantxazu Isla
    • Iñaki F. Trocóniz
    • Alicia Rodríguez Gascón

    Pharmacokinetics and Disposition 15 January 2012 Pages: 735 - 745

    

31. Statins and associated risk of pneumonia: a systematic review and meta-analysis of observational studies

    • Chun Shing Kwok
    • Jessica Ka-Yan Yeong
    • Yoon Kong Loke

    Pharmacoepidemiology and Prescription 15 November 2011 Pages: 747 - 755

    

32. Increased major bleeding risk in patients with kidney dysfunction receiving enoxaparin: a meta-analysis

    • Philipp Hoffmann
    • Frieder Keller

    Pharmacoepidemiology and Prescription 17 November 2011 Pages: 757 - 765

    

33. The importance of drug–drug interactions as a cause of adverse drug reactions: a pharmacovigilance study of serotoninergic reuptake inhibitors in France

    • Francois Montastruc
    • Agnès Sommet
    • Jean-Louis Montastruc

    Pharmacoepidemiology and Prescription 25 November 2011 Pages: 767 - 775

    

34. What’s in a label? An exploratory study of patient-centered drug instructions

    • Laura J. Sahm
    • M. S. Wolf
    • S. Mc Carthy

    Pharmacoepidemiology and Prescription 30 November 2011 Pages: 777 - 782

35. Are commonly used psychoactive medications associated with lower urinary tract symptoms?

    • Susan A. Hall
    • Nancy N. Maserejian
    • John B. McKinlay

    Pharmacoepidemiology and Prescription 04 December 2011 Pages: 783 - 791

    

36. Implementation of an automated signal detection method in the French pharmacovigilance database: a feasibility study

    • Véronique Pizzoglio
    • Ismaïl Ahmed
    • French Network of Pharmacovigilance Centres

    Pharmacoepidemiology and Prescription 06 December 2011 Pages: 793 - 799

37. Risk factors associated with adverse drug reactions in hospitalised children: international multicentre study

    • Asia N. Rashed
    • Ian C. K. Wong
    • Antje Neubert

    Pharmacoepidemiology and Prescription 14 December 2011 Pages: 801 - 810

38. Complementary and alternative medicines use by Scottish women with breast cancer. What, why and the potential for drug interactions?

    • J. S. McLay
    • D. Stewart
    • S. D. Heys

    Pharmacoepidemiology and Prescription 14 December 2011 Pages: 811 - 819

39. Drug-induced immune thrombocytopaenia: results from the Berlin Case–Control Surveillance Study

    • Edeltraut Garbe
    • Frank Andersohn
    • Hanife Kurtal

    Pharmacoepidemiology and Prescription 21 December 2011 Pages: 821 - 832

    

40. Benzodiazepine use in Belgian nursing homes: a closer look into indications and dosages

    • Jolyce Bourgeois
    • Monique M. Elseviers
    • Robert R. Vander Stichele

    Pharmacoepidemiology and Prescription 22 December 2011 Pages: 833 - 844

    

41. Effects of personality on use of medications, alcohol, and cigarettes during pregnancy

    • Eivind Ystrom
    • Margarete E. Vollrath
    • Hedvig Nordeng

    Pharmacoepidemiology and Prescription 22 December 2011 Pages: 845 - 851

42. Acute toxicity associated with the recreational use of the ketamine derivative methoxetamine

    • David M. Wood
    • Susannah Davies
    • Paul I. Dargan

    Pharmacoepidemiology and Prescription 29 December 2011 Pages: 853 - 856

43. Do Parkinson’s disease patients disclose their adverse events spontaneously?

    • Santiago Perez-Lloret
    • María Verónica Rey
    • Olivier Rascol

    Pharmacoepidemiology and Prescription 29 December 2011 Pages: 857 - 865

    

44. Managing hypertension among nursing-home residents and community-dwelling elderly in Germany: a comparative pharmacoepidemiological study

    • Sophie Lochner
    • Wilhelm Kirch
    • Christoph Schindler

    Pharmacoepidemiology and Prescription 30 December 2011 Pages: 867 - 875

    

45. EMA’s reflection on placebo does not reflect patients’ interests

    • Vittorio Bertele’
    • Rita Banzi
    • Silvio Garattini

    Point of View 02 December 2011 Pages: 877 - 879

46. Lenalidomide induced intrahepatic cholestasis in newly diagnosed patients of multiple myeloma

    • Rabindra Kumar Jena
    • Trupti Rekha Swain
    • Manorama Swain

    Short Communication 30 November 2011 Pages: 881 - 884

    

47. Impact of age, gender and haplotypes of thiopurine methyltransferase (TPMT) and inosine triphosphate pyrophosphatase (ITPA) genes on 6-mercaptopurine toxicity in children with acute lymphoblastic leukemia

    • Patchva Dorababu
    • Shaik Mohammad Naushad
    • Raghunadharao Digumarti

    Letter to the Editors 14 December 2011 Pages: 885 - 886

48. Influence of age, sex, and haplotypes of thiopurine methyltransferase (TPMT) gene on 6- mercaptopurine toxicity in children with acute lymphoblastic leukemia

    • Chakradhara Rao S. Uppugunduri
    • Marc Ansari

    Letter to the Editors 14 December 2011 Pages: 887 - 888

49. Cholesterol levels, statins, vitamin D, and associated risk of pneumonia

    • Luca Mascitelli
    • William B. Grant
    • Mark R. Goldstein

    Letter to the Editors 15 December 2011 Pages: 889 - 890

50. Interaction of flucloxacillin and quinidine

    • W. J. Comuth
    • J. A. Comuth
    • M. M. Malingré

    Letter to the Editors 28 December 2011 Pages: 891 - 893